Related by context. All words. (Click for frequent words.) 75 Phase III placebo controlled 69 Randomized Double Blind 68 BRIM2 68 Study Evaluating 67 Phase Ib clinical 67 BRIM3 67 evaluating mipomersen 67 phase Ib 67 Pivotal Phase 66 Randomized Phase 66 Initiated Phase 66 Phase Ib II 66 Bayer HealthCare Onyx Pharmaceuticals 66 Oral Fingolimod 66 APEX PD 66 LUX Lung 66 Initiate Phase 65 Phase 2b Clinical Trial 65 Phase IIb Trial 65 Meets Primary Endpoint 65 Combination REOLYSIN R 65 phase IIb study 65 REVIVE Diabetes 65 DIRECT Trial 65 Pivotal Phase III 65 Randomized Phase II 65 TAXUS ATLAS 65 Clinical Trial Results 65 placebo controlled Phase 65 multicenter placebo controlled 65 Prolongs Survival 64 Phase III Clinical Trials 64 Phase 1b clinical trials 64 Metastatic Renal Cell Carcinoma 64 Newly Diagnosed Multiple Myeloma 64 NO# [002] 64 Synta Announces 64 relapsed MM 64 Edge STudy 64 Multicenter Phase 64 registrational Phase 64 Phase III Pivotal 64 Adjuvant Treatment 64 Aflibercept 64 multicenter randomized controlled 64 Adjuvant Therapy 64 Protease Inhibitor 64 Randomized Controlled 64 Second Pivotal Phase 64 Dose Escalation 63 Randomized Double blind 63 azilsartan medoxomil 63 Subgroup Analysis 63 Cholesterol Levels SPARCL 63 CAMMS# 63 Rigel R# 63 TEMSO 63 Improves Outcomes 63 ID NCT# 63 ongoing Phase 1b 63 Phase IIIb 63 Hormone Refractory Prostate Cancer 63 Completes Patient Enrollment 63 Anthrax Toxin 63 phase IIb 63 blinded randomized placebo controlled 63 Safinamide 63 assessing T DM1 63 Pooled Analysis 63 ExTRACT TIMI 63 teriflunomide 63 sunitinib malate 63 Pharmacokinetic Study 63 IND Filing 63 Advanced Melanoma 63 Scandinavian Simvastatin Survival 63 Mg Usa 63 comparing alemtuzumab 63 phase IIa 63 Investigational Compound 63 EURIDIS 63 ENDEAVOR III 63 Cell Lymphoma 63 placebo controlled clinical 63 Adjuvant Chemotherapy 63 BOLDER II 63 number NCT# ClinicalTrials.gov 62 Phase 2a Clinical Trial 62 PANVAC VF 62 Treatment Naïve 62 Phase III Trial 62 Novel Oral 62 Phase III Clinical Trial 62 II Clinical Trial 62 Shows Promising 62 Phase 2a trial 62 Teriflunomide 62 recombinant PSMA vaccine 62 MEND CABG 62 Plaque Psoriasis 62 Shows Promise Against 62 Phase 2b Trial 62 Oral Cladribine 62 Clinical Trial Evaluating 62 pertuzumab 62 Lung Cancer Trial 62 phase IIIb 62 STRIDE PD 62 Polymerase Inhibitor 62 Placebo Controlled 62 receptor tyrosine kinase inhibitor 62 Phase Ib Clinical Trial 62 MKC# MKC# PP 62 Phase 2b Study 62 Medullary Thyroid Cancer 62 Relapsing Multiple Sclerosis 62 Drug Shows Promise 62 CYT# potent vascular disrupting 62 Carotid Revascularization Endarterectomy vs. 62 Prostate AdenoCarcinoma Treatment 62 Raloxifene Evaluation MORE 62 Acute Ischemic Stroke 62 phase IIa clinical 62 evaluating tivozanib 62 Phase 1a clinical 62 Crofelemer budesonide foam 62 Systemic Sclerosis 62 Pivotal Trial 62 Demonstrates Sustained 62 Desvenlafaxine Succinate 62 CHAMPION PCI 62 Improves Survival 62 dimebon latrepirdine 62 MIRAPEX ER 62 Completes Enrollment 62 Xelox 62 ORAL Solo 62 EXPLORE Xa 62 Prospective Randomized 62 Topline Results 62 Randomized Phase III 62 Phase IIb Clinical Trial 62 Phase III multicenter 62 Randomized Study 62 Antiviral Activity 62 Phase IIA 62 Demonstrates Significant 62 phase IIb clinical 62 AIR CF2 62 HER2 Positive Breast Cancer 62 Multicenter 62 REG2 62 Investigational Oral 62 CATIE AD 62 Unstable Angina 61 multicentre randomized 61 RE LY 61 Phase III ThermoDox 61 Pivotal Study 61 CIMZIA ™ 61 Thiarabine 61 ENDEAVOR II 61 PCI ExTRACT TIMI 61 ThermoDox ® clinical 61 Monotherapy 61 label multicenter Phase 61 Severe Sepsis 61 Enzastaurin 61 Initiates Phase II 61 midstage clinical 61 multicenter Phase 61 Asthma Intervention 61 evaluating carfilzomib 61 clinical trials Archexin 61 HCV Protease Inhibitor 61 NABTT 61 Ocrelizumab 61 LymphoStat B belimumab 61 FOLFOX6 chemotherapy regimen 61 Phase Ib study 61 Patient Enrollment 61 Cloretazine ® 61 Hormone Receptor Positive 61 INCB# [001] 61 Therapy Evaluation 61 TRANSFORMS 61 Lupus Drug 61 dose escalation Phase 61 Immunomedics Announces 61 Follicular Lymphoma 61 ENDEAVOR IV 61 Presents Positive 61 Randomized Evaluation 61 next generation URAT1 61 placebo controlled dose escalation 61 VADT 61 TMC# C# 61 Relapsed Multiple Myeloma 61 randomized Phase IIb 61 TO AVOID PREGNANCY WHILE 61 Randomized Trials 61 Demonstrates Positive 61 Phase IIb trials 61 SPIRIT FIRST 61 Preclinical Study 61 Kinase Inhibitor 61 OPT CHF 61 evaluating Actimmune 61 Platelet Inhibition 61 rALLy 61 Autologous Stem Cell Transplantation 61 rALLy clinical trial 61 Dose Ranging 61 relapsed myeloma 61 Metastatic Melanoma 61 GOUT 61 Metastatic Prostate Cancer 61 AVOREN 61 systemic Phase 1b 61 multicenter phase 61 Chronic Hepatitis C 61 Phase #/#a 61 Chemotherapy Improves 61 ABSORB clinical 61 Patients Treated With 61 VICTOR E1 61 Clinical Outcome 61 Myeloma Patients 61 XL# SAR# 61 Breaking Clinical Trials 61 Clinical Antipsychotic Trials 61 Pivotal Phase II 61 Phase IIa Clinical Trial 61 albiglutide 61 Left Ventricular Dysfunction 61 Demonstrates Efficacy 61 Phase 1b Clinical Trial 61 Soft Tissue Sarcoma 61 randomized controlled Phase 61 ADMIRE HF 61 Phase 1b 61 Preclinical Data 60 Pharmacokinetics PK 60 Adjunctive Therapy 60 tramiprosate Alzhemed TM 60 Complicated Skin 60 atypical Hemolytic Uremic Syndrome 60 Previously Untreated 60 novel VDA molecule 60 Randomized Double Blind Placebo 60 Biogen Genentech 60 Shows Efficacy 60 multicenter Phase II 60 Investigational Drug 60 Acute Myocardial Infarction 60 EVEREST II 60 initiated Phase Ib 60 Intervention Effectiveness 60 severe oral mucositis 60 Initiates Enrollment 60 Rheumatoid Arthritis Patients 60 Denufosol 60 Demonstrate Significant 60 Initiates Clinical Trial 60 AAG geldanamycin analog 60 fosbretabulin 60 Aggressive Reduction 60 Randomized Clinical Trial 60 Recurrent Breast Cancer 60 pivotal bioequivalence 60 Remission Maintenance 60 PF # [002] 60 Prodarsan R 60 Confirmatory Phase 60 multicenter randomized Phase 60 Brentuximab Vedotin SGN 60 Quinamed 60 double blinded randomized 60 randomized controlled multicenter 60 Tesetaxel 60 Clinical Outcomes Utilizing Revascularization 60 somatostatin analog 60 Relapsing Remitting Multiple Sclerosis 60 PERSEUS 60 By JENNIFER LEARN 60 Omacetaxine 60 Degarelix 60 davunetide intranasal AL 60 Endovascular Valve Edge 60 Gastrointestinal Stromal Tumors 60 oral chemotherapeutic agent 60 Testosterone MDTS R 60 Active Ulcerative Colitis 60 Clostridium difficile Infection 60 metastatic castration resistant 60 opioid naive 60 Long Lesion 60 ACTEMRA TM 60 Sangamo BioSciences Announces 60 sunitinib Sutent ® 60 Predict Risk 60 Naive Patients 60 Randomized Clinical Trials 60 Ranolazine 60 GetGoal Phase III 60 ADVANCE ILLUMINATE 60 RhuDex 60 Study Showed 60 Stent Thrombosis 60 Alemtuzumab 60 Sapacitabine 60 Combination Treatment 60 First Patient Enrolled 60 Cutaneous T 60 Stent Implantation 60 REVIVE TA 60 Cardiovascular Risk Reduction 60 Diagnostic Criteria 60 humanized interleukin 6 60 Trastuzumab DM1 60 Nicotine Vaccine 60 relapsing multiple sclerosis 60 STENT 60 fostamatinib 60 Tesmilifene 60 elacytarabine 60 CCX# 60 EntreMed Presents 60 trial evaluating PRX# 60 Vascular Disrupting Agent 60 Telik Announces 60 pralatrexate injection folate analogue 60 Annamycin 60 ADVANCE PD 60 BCIRG 60 Phase 2a clinical 60 Inflammatory Arthritis 60 MGd 60 Pertuzumab 60 Double Blind Placebo 60 NCIC CTG 60 randomized multicenter 60 Val HeFT 60 Elagolix 60 Oral Calcitonin 60 Digital Mammographic Imaging 60 Phase 1b clinical 60 Commences Phase 60 Multicenter Randomized 60 Glufosfamide 60 Traficet EN 60 neoadjuvant treatment 60 Romidepsin 60 Castration Resistant Prostate Cancer 60 Long Term Efficacy 60 Phase III randomized 60 Presents Preclinical Data 60 Antitumor Activity 60 Sorafenib HCC Assessment 60 Tolerability 60 GAMMAGARD 60 mGluR5 negative 60 gefitinib Iressa 60 Cerebral Amyloid Angiopathy 60 accumulate preferentially 60 Antibody Drug Conjugate 60 Treatment Shows Promise 60 Advanced Pancreatic Cancer 60 metastatic malignant 59 Safety Tolerability 59 novel nucleoside analog 59 AVN# Phase 59 randomized discontinuation trial 59 HuMax EGFr 59 Overactive Bladder OAB 59 HCV SPRINT 59 ENESTnd 59 Is Well Tolerated 59 deCODE AF TM 59 CARE HF 59 TASKi2 59 Screening Trial 59 CYP#A# CYP#D# 59 multicenter Phase III 59 preclinical efficacy 59 phase IIb trial 59 R# #mg BID 59 NEVO 59 Amrubicin 59 Nuvelo Announces 59 multicenter multinational 59 confirmatory pivotal 59 Treated Patients 59 bazedoxifene conjugated estrogens 59 Trial Evaluating 59 Receives Orphan Drug Designation 59 By ERIC HJERSTEDT 59 Initiates Clinical 59 PROSTVAC VF 59 Folfox 59 orally inhaled migraine 59 AVADO 59 Study Demonstrates 59 Fingolimod 59 Efficacy Results 59 Initiates Phase III 59 CALGB 59 alemtuzumab Campath 59 Hepatitis C Genotype 59 kidney urologic 59 Phase 1b trial 59 EOquin TM phase 59 Randomized Controlled Trials 59 Oral Laquinimod 59 AASLD Meeting 59 Pivotal Trials 59 ara C 59 Drug Candidate 59 PORxin TM platforms 59 evaluating Vectibix 59 Controlled Study 59 Phase 2a clinical trials 59 chemotherapy FOLFOX 59 lenalidomide Revlimid R 59 elotuzumab 59 YOUR LOCAL ANIMAL SHELTER 59 8mg/kg 59 alvespimycin 59 Non Alcoholic Steatohepatitis 59 Prednisone Against Refractory 59 Phase III randomized controlled 59 Kahalalide F 59 Aplidin 59 Benign Prostatic Hyperplasia 59 IIa clinical 59 brivanib 59 baminercept 59 multicenter randomized placebo controlled 59 NPS Pharmaceuticals Announces 59 BRAF inhibitor 59 CRLX# 59 Phase IIa trial 59 Prostate Cancer Patients 59 Curaxin CBLC# 59 Pharmacyclics Announces 59 Bezielle 59 keloid scarring 59 Drug Combo 59 HDAC Inhibitor 59 Regeneron Pharma 59 Survival Benefit 59 ZYBRESTAT TM 59 Neoadjuvant Chemotherapy 59 Vascugel ® 59 achieved CCyR 59 ritonavir boosted 59 Cimzia ® certolizumab pegol 59 Anticancer Compound 59 R#/MEM # 59 ToGA 59 omacetaxine mepesuccinate 59 galiximab 59 Anti Tumor Activity 59 Reports Preclinical Data 59 CCX# B 59 Phase Ib 59 Empatic ™ 59 Successfully Completes Phase 59 targeting miR 59 Anti CD# Antibody 59 Breast Cancer Recurrence 59 toenail onychomycosis 59 Phase III PREGNANT PROCHIEVE 59 Interferon beta 1a 59 Bipolar Depression 59 Phase 1a 59 AN# topical anti 59 Intravitreal 59 Eluting Stent 59 hormone refractory metastatic prostate 59 HCV NS5B polymerase 59 Phase IIa clinical 59 CTAP# Capsules 59 SIMPADICO 59 Phase 2a Trial 59 Ophena TM 59 Betaferon R 59 cathepsin K inhibitor 59 See CLINICAL PHARMACOLOGY 59 Tyrosine Kinase Inhibitor 59 confirmatory clinical 59 Controlled Trial 59 depsipeptide 59 Observational Study 59 including eniluracil ADH 59 pharmacokinetic PK 59 RAS MAPK pathway 59 Sirolimus Eluting Stent 59 dyskinesia PD LID 59 ORAL Sync 59 Aplidin R 59 multicenter prospective 59 Achieves Primary Endpoint 59 Dose Ranging Study 59 acyclovir Lauriad R 59 Lung Cancer Detection 59 Chronic Myeloid Leukemia 59 multicentre randomized double 59 Vicriviroc 59 bapineuzumab AAB 59 Refractory Hodgkin Lymphoma 59 ganetespib 59 pharmacokinetic pharmacodynamic 59 MERLIN TIMI 59 Sipuleucel T 59 Well Tolerated 59 Treatment Regimen 59 Pfizer Discontinues 59 Perifosine KRX 59 Phase III ALLEGRO 58 #:#-#,# CrossRef Medline [002] 58 Epratuzumab 58 Placebo Controlled Study 58 Wisconsin Sleep Cohort 58 phase 2a 58 Budesonide foam crofelemer 58 CALERIE 58 Parathyroid Hormone 58 Campath alemtuzumab 58 Aortic Stenosis 58 PLX STROKE targeting 58 GLPG# 58 Matrix Phase 2b 58 Diabetic Foot Ulcer 58 oncolytic virus therapies 58 Randomised 58 Truvada tablets 58 Vitaxin 58 pan histone deacetylase 58 First Patient Dosed 58 Screening Trial DMIST 58 Evaluation Program CTEP 58 Archexin 58 humanized therapeutic 58 PRIMO CABG2 58 Cardiotoxicity 58 ST Elevation Myocardial 58 evaluating satraplatin plus 58 Phase III Trials 58 ICON7 58 ONTARGET 58 PROTEGE 58 desvenlafaxine succinate 58 Celecoxib APC trial 58 Preclinical Models 58 sapacitabine CYC# 58 ATAC Arimidex Tamoxifen Alone 58 gastrin analogue TT 58 Diabetic Nephropathy 58 RECORD1 58 Periodic Screening Diagnosis 58 subanalysis 58 Clinical Trial Data 58 Capesaris 58 Infarct 58 Unresectable 58 Tipranavir 58 Malignant Melanoma 58 PreCISe 58 Hepatitis C Infection 58 ASTEROID 58 TNFerade TM 58 NSABP B 58 IMPACT DCM 58 ThermoDox R 58 Anthracycline 58 Initiate Phase III 58 rosuvastatin #mg 58 LungAlert TM 58 Spectrum Pharmaceuticals Announces 58 Cognitive Function 58 BR.# 58 Salix Pharmaceuticals Announces 58 refractory chronic lymphocytic 58 Previously Treated 58 oral FTY# 58 BLOOM Behavioral modification 58 ZACTIMA 58 NSABP C 58 visilizumab 58 sarcoma melanoma 58 HQK 58 lintuzumab SGN 58 Improve Survival 58 huC# DM4 58 multicentre prospective 58 Imetelstat 58 dasatinib Sprycel ® 58 Tarceva TM 58 CD# CEA 58 PET FROM 58 DEB# 58 Presents Preclinical 58 ONCONASE R 58 miconazole Lauriad ® 58 Etanercept 58 VIVUS Announces 58 Cancer Incidence Mortality 58 trials BLISS 58 Recurrent Glioblastoma 58 dose escalation clinical 58 Xanafide 58 Carotid Stenting 58 ChronVac C R 58 CLARITY study 58 AVERROES 58 SORT OUT 58 sorafenib tablets 58 PHASE III 58 IMA# 58 Suppl. 58 mGluR2 NAM 58 Tanespimycin 58 TKB# 58 Capsules CII 58 Panzem NCD 58 CINQUIL 58 oral prodrug 58 thalidomide Thalomid 58 Telik logo TELINTRA 58 PRoFESS 58 Investigator Initiated 58 metastatic colorectal 58 Elotuzumab 58 HGS# 58 Catena ® 58 Investigational Treatment 58 indolent follicular non 58 plus Copegus R 58 familial amyloidotic polyneuropathy FAP 58 PRN FDA Approves 58 prospective multicentre 58 trastuzumab DM1 T DM1 58 Genes Predict 58 Initiates Phase 58 Myelodysplastic Syndrome MDS 58 TAXUS VI 58 morphometric vertebral fractures 58 FDA Approves Drug 58 angiotensin analog 58 ocular formulation 58 Phase IIB 58 paclitaxel poliglumex 58 Subtypes 58 Venous Thromboembolism 58 Phase Ib IIa 58 Migraine Drug 58 complement inhibitor eculizumab 58 riociguat 58 receiving chemoradiation therapy 58 Trandolapril 58 pain palliation 58 ziprasidone Geodon 58 Inflammatory Markers 58 BiTE antibodies targeting 58 Dr. Gabriel Lasala 58 GRNCM1 58 Daclizumab 58 QLT# 58 Phase #b/#a clinical 58 HER2 Positive 58 Zemplar Capsules 58 heFH 58 brivaracetam 58 HCV Genotype 58 Lu AA# 58 metastatic hormone refractory 58 Accelr8 Announces 58 dirucotide MBP# 58 APTIVUS 58 ROCKET AF 58 opioid induced bowel dysfunction 58 Betaferon ® 58 recurrent metastatic 58 REYATAZ r 58 Bosentan 58 PRE SURGE 58 polycythemia vera essential thrombocythemia 58 Patients Receiving 58 TransVax 58 Peginterferon 58 Hepatic Encephalopathy 58 Angiographic 58 Patient Accrual 58 SurModics Bravo 58 guanfacine extended release 58 Phase IIa 58 Clinical Trials Update 58 axitinib 58 TELINTRA R 58 phase Ib clinical 58 unique alkylating agent 58 forodesine 58 ixabepilone 58 Slow Progression 58 myelodysplastic myeloproliferative diseases 58 Clinical Efficacy 58 worsening thrombocytopenia 58 Aurora Kinase 58 Iloperidone 58 Cannabinor 58 aldehyde dehydrogenase ALDH2 deficiency 58 Febuxostat 58 evaluating satraplatin 58 SUTENT ® 58 Testosterone MDTS ® 58 Initiates Phase 2b 58 Aggressive Drug Evaluation 58 First Patient Treated 58 atacicept 58 Slows Progression 58 Stent Restenosis 58 Sandostatin R 58 PROSTVAC TM 58 IIa Clinical Trial 58 pharmacokinetics PK 58 transthyretin TTR mediated amyloidosis 58 Ophena 58 Myelofibrosis 58 Heart Failure Patients 58 CYT# QbG# 58 antiretroviral naïve 58 safinamide 58 AZILECT R 57 MAGE A3 ASCI 57 Cancer Cachexia 57 Systemic Delivery 57 ALN VSP Phase 57 SPRYCEL ® 57 JAK2 Inhibitor 57 Phase #b/#a 57 Pharmacodynamic 57 Cerebril TM 57 recurrent glioblastoma multiforme 57 FDA Approvals 57 systemic anaplastic large 57 OncoVex 57 STEALTH C 57 Transdermal Patch 57 intravesical infusion therapy 57 lead Aganocide compound 57 MKC# MT 57 pharmacokinetic PK study 57 RoACTEMRA 57 Antiviral Therapy 57 Hsp# Inhibitor 57 Therapy Improves 57 Phase Ia 57 Dose Response 57 HYVET 57 Adalimumab 57 sorafenib Nexavar 57 Bone Metastases 57 Temsirolimus 57 SPIRIT IV 57 DAC HYP 57 multicenter randomized double 57 Syncria albiglutide 57 Multicenter Randomized Double 57 Laryngeal Cancer 57 mGluR2 positive 57 Multiple Ascending Dose 57 PROVENGE ® 57 ataluren 57 bone marrow reticulin deposition 57 Luramist TM 57 aripiprazole Abilify 57 Wadih Arap 57 COPERNICUS 57 Arch Neurol 57 treatment naïve genotype 57 dependent kinase inhibitor 57 Receives Orphan Drug 57 erlotinib Tarceva ® 57 Tasimelteon 57 APPRAISE 57 memantine HCl 57 mg BID dose 57 Meta Analysis 57 Relapsed Refractory 57 Deforolimus 57 relapsing remitting MS RRMS 57 Alfimeprase 57 evaluating Prochymal 57 dosing cohorts 57 orally administered inhibitor 57 testing huN# DM1 57 Urocortin 2 57 Clin Oncol 57 Bosutinib 57 Treat Heart Failure 57 HDL Selective Delipidation 57 Hepatocellular Carcinoma 57 donepezil Aricept 57 HCV RESPOND 2 57 generation antisense inhibitor 57 ECASS 57 AVONEX ® 57 Idenix Pharmaceuticals Reports 57 oral ghrelin agonist 57 demonstrated antitumor activity 57 CML CP 57 Subgroup analysis 57 melphalan prednisone 57 Phase 2b study 57 oral ridaforolimus 57 Thorough QT 57 Refractory Angina 57 randomized multicenter trial 57 R lenalidomide 57 hour bronchodilation 57 Advanced Renal Cell 57 Phase IIa trials 57 Poster Discussion 57 dose escalation trial 57 phase III ACCLAIM 57 WE WILL CONTINUE TO 57 rash pruritus nausea 57 Optical Coherence Tomography 57 Cholinesterase Inhibitors 57 Long Term Outcomes 57 registrational trial 57 metaglidasen 57 AVASTIN 57 Chronic Lymphocytic Leukemia CLL 57 prospective multicenter 57 biologic DMARD 57 SUCCEED trial 57 Hemodialysis Patients 57 Virus Linked 57 Anticancer Drug 57 oral rivaroxaban 57 controlled multicenter Phase 57 AIR2 Trial 57 Stem Cell Transplants 57 GW# [003] 57 Minera IRL Announces 57 PEG SN# 57 investigational HCV polymerase 57 Test Detects 57 PRT# 57 Phase III AFFIRM 57 metastatic castrate resistant 57 Hepatotoxicity 57 IMPDH inhibitor 57 Disease Modifying 57 Panzem R 57 PMX # heptagonist 57 randomized discontinuation 57 human IgG1 monoclonal 57 REMINYL ® 57 formerly LymphoStat B 57 oral nucleoside analogue 57 PD LID 57 Immunotherapeutic 57 enzastaurin 57 sargramostim 57 Secondary Hyperparathyroidism 57 tolerability pharmacokinetics 57 Randomized controlled 57 steroid refractory ulcerative 57 HuMax 57 non nucleoside inhibitor 57 DNA methyltransferase inhibitors 57 Nephrol Dial Transplant 57 Relapsing remitting 57 Begins Dosing 57 Phase 2a 57 budesonide foam 57 Lomitapide 57 Severe Asthma 57 Phase IIIb clinical 57 telomerase therapeutic 57 SYN# 57 dexpramipexole 57 Phase IIb III 57 bavituximab monotherapy trial 57 dosing cohort 57 ANN INTERN MED 57 Gene Linked 57 AIR CF1 57 Alzhemed TM 57 LHRH receptor positive 57 Lung Injury 57 allosteric modulator NAM 57 targeted radiotherapeutic 57 Granted Orphan Drug 57 placebo controlled Phase III 57 treatment naive genotype 57 Phase III ADT 57 Epothilone D 57 Elderly Patients 57 Anti Tumor 57 Multicenter Study 57 GISSI 57 TBC# 57 PEG IFN 57 AS# amonafide L malate 57 prospective randomized placebo 57 Viral Suppression 57 Therapy Shows Promise 57 adalimumab Humira 57 Dose Finding 57 BioSante LibiGel Phase III 57 Plicera 57 Overactive Bladder 57 VEGFR2 inhibitor 57 ST Segment Elevation 57 granted Ortec 57 PSMA ADC 57 Antigen Specific 57 REVIVE 57 Preclinical Efficacy 57 Dapagliflozin 57 Hypoactive Sexual Desire Disorder 57 Lupus Nephritis 57 Renal Cell Carcinoma 57 dose escalation phase 57 Phase III Pivotal Trial 57 antibody MAb 57 Pralatrexate 57 Tumor Response 57 mertansine 57 Placebo Controlled Trial 57 basal bolus regimen 57 stage IIIb IV 57 brand ciclesonide HFA 57 myocardial infarction ventricular fibrillation 57 benign prostatic hyperplasia enlarged 57 PEGylated interferon beta 1a 57 recurrent malignant glioma 57 EQUATE OB 57 recurrent metastatic ovarian cancer 57 randomized crossover 57 Appears Safe 57 PEGINTRON TM 57 Ceflatonin 57 fluticasone furoate 57 cetuximab Erbitux R 57 Alocrest 57 Myelodysplastic Syndromes 57 Carfilzomib 57 randomized Phase III 57 Phase 2b trial 57 Phase 2b monotherapy 57 dasatinib Sprycel 57 CLL8 57 Serious Infections 57 comparing XIENCE V 57 Left Ventricular 57 Lung Cancer Survival 57 lexidronam injection 57 chronic myeloid 57 Am J Gastroenterol 57 Primary endpoints 57 ABSORB trial 57 INSPIRE Trial Phase III 57 Chemoradiation 57 tanespimycin 57 Genes Identified 57 FDA APPROVES 57 ospemifene 57 Phase Ib clinical trials 57 PATENT FOR 57 HuMax CD#b 57 Renal Impairment 57 endometriosis ovarian cysts 57 icatibant 57 enoximone capsules 57 PI3K/Akt pathway inhibitor 57 Sym# 57 Phase IIIb study 57 Ozarelix 57 deCODE ProstateCancer TM 57 Blind Placebo Controlled 56 MEMS ICs 56 LHON 56 Albuferon TM 56 INxin TM 56 Drug Prevents 56 CONQUER OB 56 Pafuramidine 56 Pharmacokinetic 56 Statistically Significant 56 RAPAFLO R 56 papillary renal cell carcinoma 56 Late Breaker 56 Feasibility Trial 56 OvaRex ® MAb